US House Committee Clears Bills To Prevent Pay-For-Delay Deals, Assure Generic Access To Samples
Executive Summary
Legislation on patent settlement agreements will not be retroactive; CREATES Act amended to give brand companies affirmative defense to litigation.
You may also be interested in...
US Ambrisentan Approvals Hint At Different Commercial Approaches
Four different firms have simultaneously received FDA approval for ambrisentan generics of Gilead’s Letairis. But different safety programs suggest Zydus Pharma may be taking a different commercial approach to the other three generics firms.
CREATES Act Has a Penalty Problem
Republican House Energy and Commerce Committee members say potentially taking a company's revenue for blocking a generic company from obtaining samples, rather than profit, is excessive.
FTC’s New Commissioner, Alvaro Bedoya, May Bolster Tougher Stance On Pharma Oversight
Democrats gain majority on Federal Trade Commission with Bedoya’s swearing in. His positions on technology and digital privacy suggest he will align with commissioners who have advocated stricter review of pharma mergers.